Opioid Epidemic Services
The current opioid epidemic has affected nearly
every aspect of American society.
The Bizzell staff is committed to providing solutions to address the current opioid epidemic. We will continue to lead efforts to address substance use disorders and prevent overdoses by engaging providers and first responders through education.
SUBSTANCE USE DISORDERS: Addressing the Opioid Epidemic
Drug overdose deaths continue to increase in the U.S. From 1999 to 2017, more than 702,000 people have died from a drug overdose. In 2017, a staggering 70,237 deaths by overdose were reported, making drug overdose the leading cause of injury-related death in the U.S. Of those deaths, almost 68% involved a prescription or illicit opioid. Opioids are entering our homes in a conventional manner and harming our loved ones in unconventional ways.
Deaths from opioids are having a devastating impact in America. From 2010 to 2017, the number of opioid involved overdose deaths in the U.S. more than doubled. According to the Centers for Disease Control and Prevention, from 1999 to 2018, almost 450,000 people died of an opioid drug overdose. In 2018, nearly 70 percent of the more than 67,000 deaths by drug overdose involved a prescription or illicit opioid. Opioid overdose deaths increased by 4.6 percent from 2018 to 2019, despite a significant decrease in opioid use disorders from 2.0 million to 1.6 million.
This epidemic is taking a toll not only on the individuals struggling with opioid use disorders (OUD) but also on American communities, families, and businesses. In 2017, nearly 2 million children had a parent with an opioid use disorder (OUD); 240,000 had lost a parent due to an opioid overdose. Businesses suffer also. Each year, an estimated two million workers are absent from the labor force due to OUDs, and that number is growing. In 2019, 10.1 million people misused opioids, with 9.7 million (97.7 percent) of those misusing prescription pain relievers.
Bizzell is committed to data-driven, research-informed, innovative solutions to address the current opioid epidemic as well as the other substance use disorders that are continuing to effect individuals, families, and businesses.
Our subject matter experts effectively collaborate with treatment programs, business leaders, professional organizations, accreditation bodies, governmental entities, individuals in recovery, and other stakeholders, to address the opioid epidemic using a variety of strategies.
IDENTIFYING BUSINESS SOLUTIONS TO THE OPIOID EPIDEMIC
- As a U.S. Chamber of Commerce Fellow and substance use disorders expert, Dr. Anton Bizzell, Bizzell CEO, has facilitated business leadership discussions and resource sharing on the Sharing Solutions campaign, visiting ten of the communities most severely impacted by the opioid epidemic. Topics included supporting employees, applying competencies, engaging communities, and fostering changes in business practices.
- Bizzell planned, hosted, and supported policy stakeholder meetings on clinically sound and cost-effective delivery and financing approaches for providing medications, behavioral therapies, and recovery support services, to ensure sustainable outcomes [Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Medication Assisted Treatment-Prescription Drug and Opioid Addiction (MAT-PDOA) Targeted Capacity Expansion efforts].
PROVIDING TECHNICAL ASSISTANCE TO OPIOID TREATMENT PROGRAMS AND STATE AGENCIES
- Bizzell helped opioid treatment programs (OTPs) and state agencies identify and implement necessary changes for accreditation. Bizzell provided technical assistance to more than 1,400 OTPs, provider groups, and state systems responsible for developing policy and programming for medication-assisted treatment [SAMHSA Opioid Treatment Program-Quality (OTP–Q), funded through the Division of Pharmacologic Therapies].
DEVELOPING AND PROVIDING OUD TRAINING, CURRICULUM, AND EDUCATION MATERIALS FOR HEALTHCARE PROFESSIONALS AND OTHER STAKEHOLDERS
- Bizzell teamed with Boston University to provide logistics for provider trainings throughout the U.S. on the safe use of extended-release/long-acting (ER/LA) analgesics [Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) grant].
- Bizzell supports innovative and strategic dissemination of evidence-based medical, clinical, and technological interventions to address OUDs, through Continuing Medical Education (CME), podcasts, online buprenorphine trainings, and interactive videos on OUD prescribing options in various medical settings. Bizzell collaborates with leading health care organizations, professional associations, and research institutions to advance knowledge and treatment of OUDs through outreach, education, and through support of the dissemination-focused Mentor-Facilitated Training program [National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN)].
- Bizzell developed a robust training curriculum including webinars, online modules, and in-person education that has equipped thousands of qualified health professionals with the skills and readiness needed to meet the challenges of OUDs. Our team of behavioral health subject matter experts continue to work with diverse clinical professionals across institutions and agencies, as well as state and local governments, to address the epidemic on a national, regional, and local level./li>
- Bizzell Health Webinars offer timely information and trainings for providers on topics including Performance Improvement, Community Engagement, Motivational Interviewing, and OTP Accreditation. Bizzell is an approved provider of continuing education for NAADAC: The Addiction Professional’s Association.
- In August 2020, Bizzell launched the Behavioral Health Advancement Resource Center (BHARC), a central hub with innovative tools, resources, and insights to support the behavioral health community. BHARC provides information on various public health issues including substance abuse, mental health, vulnerable populations, HIV/AIDS, tobacco research, suicide prevention, maternal and child health, and more.